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OBJECTIVE — The role of oxidative damage in the pathogenesis of metabolic syndrome is
poorly understood.
RESEARCH DESIGN AND METHODS — A detailed cross-sectional study was per-
formedtoassesstherelationshipbetweenlipidoxidationproducts,-glutamyltransferase,high-
sensitivity C-reactive protein (hs-CRP), and phospholipase activities with respect to the
metabolic status in a cohort of otherwise healthy individuals.
RESULTS — Atotalof179individuals(87menand92women)aged4314years(mean
SD) participated in this study. There were no differences in the levels of plasma F2-isoprostanes,
hydroxyeicosatetraenoic acids, cholesterol oxidation products, and phospholipase activities in
individuals with features of metabolic syndrome. In multivariate analyses, serum hs-CRP was a
consistent independent predictor of metabolic syndrome.
CONCLUSIONS — Minimal changes were observed in multiple markers of oxidative dam-
age in a well-characterized cohort of individuals with features of metabolic syndrome.
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S
tudies that have examined oxidative
damage in healthy individuals with
features of metabolic syndrome
have shown conﬂicting results (1–6). In
some, markers of oxidative damage have
beenobservedtobeminimallyaltered(1–
3), whereas in others, they were signiﬁ-
cantly elevated in those with features of
metabolic syndrome (4–6). To resolve
these discrepancies in the literature, we
conducted a detailed cross-sectional
study and measured multiple plasma and
urinary markers of oxidative damage in a
cohort of healthy individuals. In this
study, the metabolic syndrome was de-
ﬁnedusingacombinationofdifferentdef-
initions based on the modiﬁed American
Heart Association (AHA)/National Heart,
Lung, and Blood Institute (NHLBI) crite-
ria (7) and the homeostasis model assess-
ment of insulin resistance (HOMA-IR)
index (8).
RESEARCH DESIGN AND
METHODS— We included otherwise
healthy individuals with no evidence of
vascular diseases in this study. The meta-
bolic syndrome status of individuals was
deﬁned using modiﬁed criteria of the
AHA/NHLBI (7) and the HOMA-IR index
(8). The blood and urine samples were
collected, centrifuged, and stored at
80°C before analyses. Lipid proﬁle,
high-sensitivity C-reactive protein (hs-
CRP), insulin, -glutamyltransferase
(GGT), phospholipase A2, and platelet-
activating factor acetylhydrolase (PAF-
AH) activities were measured in serum.
Plasma F2-isoprostanes, total hydroxyei-
cosatetraenoic acid (HETEs) [a mixture
of 5(S)-, 12(S)-, 15(S)-, and 20-HETE],
cholesterol oxidation products, allan-
toin, and urinary 8-hydroxy-2-deox-
yguanosine (8-OHdG) were measured by
gas chromatography–mass spectroscopy
(9–12), and uric acid was measured in
plasma using high-performance liquid
chromatography. Different metabolites of
urinary F2-isoprostanes were measured,
namely 8-iso-F2-isoprostanes, 2,3-dinor-
F2-isoprostanes, and 2,3-dinor-5,6-
dihydro-F2-isoprostanes (10). Urinary
creatinine levels were measured to stan-
dardize urinary F2-isoprostanes and
8-OHdG and cholesterol to standardize
cholesterol oxidation product levels.
Powercalculations,performedapriorion
the primary variables, indicated that a
minimum sample size of 160 was re-
quiredforthisstudy.Univariateandmul-
tivariate regression analyses were
performed, taking into account multiple t
testing.
RESULTS— Of the 179 study partici-
pants, 87 were men and 92 were women
(aged 43  14 years [mean  SD]). Of
these, 21 (12%) were obese, 71 (40%)
were overweight, 78 (44%) were normal
weight, and 9 (5%) were underweight.
None of the study participants had diabe-
tes based on their fasting glucose levels.
Based on the modiﬁed AHA/NHLBI crite-
ria, a total of 14 (8%) individuals fulﬁlled
the criteria for metabolic syndrome; 66
(37%) had one or two risk components;
and 99 (55%) did not have any risk com-
ponent of metabolic syndrome. More
men had one or two risk components of
metabolic syndrome than women (sup-
plementaryTable1,availableinanonline
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-2124/DC1). A
signiﬁcant correlation was observed be-
tween the number of risk components of
metabolic syndrome with respect to the
HOMA-IR index (r  0.699, P  0.001).
Althoughtherewerenodifferencesinage,
diastolicbloodpressure,fastingserumin-
sulin, HOMA-IR index, and the number
of risk components of metabolic syn-
drome, several differences in hemody-
namic and metabolic parameters were
observed between the sexes. Men had
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fasting serum glucose, triglycerides, and
BMI, whereas women had higher levels of
HDLs (supplementary Table 1). To take
into account these differences, sex-speciﬁc
analyses were subsequently performed.
There were no signiﬁcant differences
in the levels of the esteriﬁed and free
forms of plasma F2-isoprostanes; total
HETEs; 7-, 24-, and 27-hydroxycholes-
terol; plasma allantoin; serum PLA2 and
PAF-AH activities; urinary 8-OHdG (a
marker of oxidative damage to DNA and
the DNA precursor pool that is known to
be elevated in diabetic subjects) (13); and
urinarytotalF2-isoprostanesaccordingto
the different risk categories of metabolic
syndrome in men and women. This con-
clusionwasnotchangedaftervalueswere
corrected for their precursors (arachi-
donicacidorcholesterol)(supplementary
Tables 2–4, available in an online appen-
dix). On the other hand, serum hs-CRP
correlated signiﬁcantly with the number
of risk components of metabolic syn-
drome and the HOMA-IR index in both
men and women (Ptrend0.001). In
women, plasma uric acid and serum GGT
were increased in individuals with a
higher number of risk components of
metabolic syndrome and the HOMA-IR
index, whereas in men, plasma 7-
hydroxycholesterol correlated signiﬁ-
cantly with the HOMA-IR index (but not
with the number of the risk components
of metabolic syndrome).
To identify predictors of metabolic
syndrome, signiﬁcant variables were in-
cluded in a stepwise multivariable model
(Table 1). We observed serum hs-CRP to
be a consistent predictor of metabolic
syndrome using the two different criteria
in both men and women. With use of the
modiﬁed AHA/NHLBI criteria, serum hs-
CRPaccountedfor	19%ofthevariation
inthenumberofriskcomponentsofmet-
abolic syndrome in men, whereas serum
hs-CRP and GGT explained 	24% varia-
tion in women.
CONCLUSIONS — The levels of
oxidation products of arachidonic acid
(F2-isoprostanes and total HETEs),
phospholipase activities (PLA2 and PAF-
AH), certain cholesterol oxidation products
(such as 24- and 27-hydroxycholesterol),
8-OHdG,andallantoin(aproductofoxida-
tive damage to uric acid) were unchanged
across the different risk categories of meta-
bolic syndrome.
The temporal involvement of oxida-
tive damage in the pathological processes
of metabolic syndrome is poorly under-
stood. In a study among Indian Mauri-
tians with impaired glucose metabolism,
plasma F2-isoprostanes were observed to
be increased during the initial pre-
diabetic and early diabetic states, which
led to the suggestion that oxidative dam-
age may precede the development of dia-
betes in healthy individuals (6). In
another study that examined oxidative
damage in type 2 diabetes, the levels of
urinary F2-isoprostanes were found to be
elevated only in those with at least 7 years
of disease (14), which indicates that oxi-
dative damage is possibly a late conse-
quent of diabetes. In the present cohort,
wefoundserumhs-CRP(butnotmarkers
of oxidative damage) to correlate closely
with the number of risk components of
metabolic syndrome and the HOMA-IR
index. These data seem to support previ-
oussuggestionsthatlow-gradeinﬂamma-
tory changes may occur early before the
development of cardiovascular diseases
(14).
In this study, we observed sex-
speciﬁc differences in the correlation of
certain markers of oxidative damage and
the risk categories of metabolic syn-
drome.Forexample,plasmauricacidand
serum GGT correlated signiﬁcantly with
features of metabolic syndrome in
women,whereasplasma7-hydroxycho-
lesterol (15) correlated signiﬁcantly with
the HOMA-IR index in men. The reasons
for these observations are not known, al-
though sex-speciﬁc factors such as the
differences in the hormonal and meta-
bolic proﬁles may (at least in part) pro-
vide explanations for these ﬁndings.
Tosummarize,minimalchangeswere
observedinmultiplemarkersofoxidative
damage in a well-characterized cohort of
individuals with features of metabolic
syndrome.
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